PT892849E - Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico - Google Patents

Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico

Info

Publication number
PT892849E
PT892849E PT97903840T PT97903840T PT892849E PT 892849 E PT892849 E PT 892849E PT 97903840 T PT97903840 T PT 97903840T PT 97903840 T PT97903840 T PT 97903840T PT 892849 E PT892849 E PT 892849E
Authority
PT
Portugal
Prior art keywords
receptor
obeso
gene
hematopoietic
cells
Prior art date
Application number
PT97903840T
Other languages
English (en)
Portuguese (pt)
Inventor
Snodgrass H Ralph
Cioffi Joseph
Thomas J Zupancic
Alan W Shafer
Adel A Mikhail
Bruce A Barut
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/618,957 external-priority patent/US6355237B1/en
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Publication of PT892849E publication Critical patent/PT892849E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/355—Leptin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
PT97903840T 1996-01-23 1997-01-21 Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico PT892849E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58991596A 1996-01-23 1996-01-23
US08/618,957 US6355237B1 (en) 1994-09-14 1996-03-20 Methods for using the obese gene and its gene product to stimulate hematopoietic development
US71329696A 1996-09-13 1996-09-13

Publications (1)

Publication Number Publication Date
PT892849E true PT892849E (pt) 2006-08-31

Family

ID=27416556

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97903840T PT892849E (pt) 1996-01-23 1997-01-21 Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico

Country Status (10)

Country Link
EP (2) EP1731164A1 (https=)
JP (2) JP4018142B2 (https=)
AT (1) ATE320479T1 (https=)
AU (1) AU731685C (https=)
CA (1) CA2244693A1 (https=)
DE (1) DE69735477T2 (https=)
DK (1) DK0892849T3 (https=)
ES (1) ES2260784T3 (https=)
PT (1) PT892849E (https=)
WO (1) WO1997027286A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
DK0877803T3 (da) * 1996-01-04 2005-09-19 Amgen Inc OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
FR2767136B1 (fr) * 1997-08-06 2004-08-27 Genset Sa Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
CA2341754A1 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
ES2308852T3 (es) 1998-11-04 2008-12-01 Serono Genetics Inst Sa Secuencias genomicas y completas de cdna de apm1 humano especifico para adipocitos y marcadores bialelicos de los mismos.
DE60041912D1 (de) 1999-02-10 2009-05-14 Serono Genetics Inst Sa Polymorphe marker des lsr-gens
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
WO2019126071A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
US20210228685A1 (en) * 2018-07-24 2021-07-29 Bioreg Llc Improved weight loss therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor

Also Published As

Publication number Publication date
JP4018142B2 (ja) 2007-12-05
DE69735477D1 (de) 2006-05-11
DE69735477T2 (de) 2006-11-30
CA2244693A1 (en) 1997-07-31
ES2260784T3 (es) 2006-11-01
EP0892849B1 (en) 2006-03-15
EP0892849A4 (en) 2004-08-25
WO1997027286A1 (en) 1997-07-31
AU1831197A (en) 1997-08-20
JP2001510982A (ja) 2001-08-07
DK0892849T3 (da) 2006-07-24
EP0892849A1 (en) 1999-01-27
AU731685C (en) 2002-08-22
AU731685B2 (en) 2001-04-05
ATE320479T1 (de) 2006-04-15
EP1731164A1 (en) 2006-12-13
JP2007163502A (ja) 2007-06-28

Similar Documents

Publication Publication Date Title
PT892849E (pt) Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico
DE59912118D1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
Kassem Stem cells: Potential therapy for age‐related diseases
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
Géraudie et al. Gene expression during amphibian limb regeneration
NO984729L (no) In vivo genoverf°ringsmetoder for leging av sÕr
DE69333731D1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
ATE224736T1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
DE69435026D1 (de) Ein homeobox-faktor der insulin-expression in pankreatischen inselnzellen stimuliert
SE9702305D0 (sv) New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
DE69728897D1 (de) Saeugetierchemokine
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
ATE144791T1 (de) Innerhalb des alpha-locus gelegenes t-zell- rezeptor-gen und dna-konstruktionen
DE69130704D1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns-sequencen, und ihre herstellung und vewendung.
Zornetzer et al. Gene expression in mouse neuroblastoma cells: properties of the genome.
DE69927669D1 (de) Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
HUP0004577A1 (hu) Kationos nukleinsav transzfekciós ágensek új csoportja
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
Donoghue et al. Acute Response of Engineered Cardiac Tissue to Pressure and Stretch
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung